KEY TAKEAWAYS The NeoFox phase II trial aimed to assess the feasibility and efficacy of a neo-adjuvant treatment regimen in pts with stage II/III colon cancer. The Ad hoc observations suggested Foxy-5 impairs invasion and induces downstaging in stage II/III colon...
![Neo-Adjuvant Foxy-5 Shows Promise in Stage II/III Colon Cancer](https://oncweekly.com/wp-content/uploads/2023/03/Gastrointestinal-8-1080x675.jpeg)